| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5703140 | American Journal of Ophthalmology | 2017 | 27 Pages |
Abstract
Bimatoprost SR demonstrated favorable efficacy and safety through 6Â months. All dose strengths were comparable to topical bimatoprost in overall IOP reduction through week 16. A single administration controlled IOP in the majority of patients for up to 6Â months.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Richard A. Lewis, William C. Christie, Douglas G. Day, E. Randy Craven, Thomas Walters, Marina Bejanian, Susan S. Lee, Margot L. Goodkin, Jane Zhang, Scott M. Whitcup, Michael R. Robinson,